- Price Band fixed at ₹ 420 per equity share to ₹ 441 per equity share of the face value of ₹2 each
- Anchor Investor Bidding Date – Thursday, November 28, 2024
- Bid /Offer Opening Date – Friday, November 29, 2024, and Bid/ Offer Closing Date – Tuesday, December 3, 2024
- Bids can be made for a minimum of 34 Equity Shares and in multiples of 34 Equity Shares thereafter
NE BUSINESS BUREAU
AHMEDABAD, NOV 28
Suraksha Diagnostic Limited, a leading integrated diagnostic chain, on Wednesday announced it proposes to open its its ₹846 crore initial public offering on Friday, November 29, 2024. The Anchor Investor Bidding Date is one Working Day prior to Bid/Offer Opening Date, being Thursday, November 28, 2024. The Bid/ Offer Closing Date is Tuesday, December 3, 2024.
The Kolkata-based company, known for its comprehensive pathology, radiology, and medical consultation services, operates an extensive network across eastern India, has fixed a price band of ₹420 to ₹441 per equity share. Bids can be made for a minimum of 34 Equity Shares and multiples of 34 Equity Shares thereafter. Retail investors thereby must make a minimum investment of ₹14,994. For big NII, the minimum lot size investment is 67 lots (2,278 shares), or ₹1,004,598, and for small NII, it is 14 lots (476 shares), or ₹209,916.
The Initial Public Offering is an Offer For Sale of up to 19,189,330 Equity Shares, comprising up to 2,132,148 Equity Shares by Dr. Somnath Chatterjee, up to 2,132,148 Equity Shares by Ritu Mittal, up to 2,132,148 Equity Shares by Satish Kumar Verma, up to 10,660,737 Equity Shares by Orbimed Asia II Mauritius Limited, up to 799,556 Equity Shares by Munna Lal Kejriwal, and up to 1,332,593 Equity Shares by Santosh Kumar Kejriwal.
Being an Offer for sale, all proceeds will go to the Selling Shareholders and Company will not receive any proceeds from the issue.
Half of the issue size has been set aside for qualified institutional buyers (QIBs), 35% for retail individual investors (RIIs) and 10% for non-institutional investors (NIIs).
It was established in 2005 and provides medical consulting, radiological testing, and pathology services. As of June 30, 2024, it has 215 client touchpoints, including 49 diagnostic centers and 166 sample collection centers spread throughout West Bengal, Bihar, Assam, and Meghalaya, in addition to its central reference laboratory and eight satellite laboratories. The organization provides its clients with medical consultation services both online and offline through 44 diagnostic centres, which contain 120 polyclinics staffed by over 750 doctors.
For the quarter ended on June 30, 2024, Suraksha Diagnostic reported a net profit of ₹7.67 crore with a revenue of ₹61.85 crore. The company’s bottomline stood at ₹23.13 crore with a revenue of ₹222.26 crore in the financial year ended on March 31, 2024.
The Equity Shares of the Company are proposed to be listed on BSE Limited and the National Stock Exchange of India Limited.
ICICI Securities Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited are the Book Running Lead Managers to the Offer.
